The estimated Net Worth of Michael S Brown is at least $16.2 Миллион dollars as of 14 June 2024. Michael Brown owns over 1,535 units of Regeneron Pharmaceuticals stock worth over $3,329,610 and over the last 21 years he sold REGN stock worth over $12,140,594. In addition, he makes $719,993 as Independent Director at Regeneron Pharmaceuticals.
Michael has made over 66 trades of the Regeneron Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 1,535 units of REGN stock worth $960,296 on 14 June 2024.
The largest trade he's ever made was exercising 43,000 units of Regeneron Pharmaceuticals stock on 11 February 2005 worth over $258,000. On average, Michael trades about 4,159 units every 80 days since 2003. As of 14 June 2024 he still owns at least 2,917 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Michael Brown stock trades at the bottom of the page.
Dr. Michael S. Brown M.D. serves as Independent Director of the Company. He holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, and is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine, and Foreign Member of the Royal Society of London. Dr. Brown retired as a member of the board of directors of Pfizer Inc. in 2012. Dr. Brown’s distinguished scientific and academic background, including his receipt of the Nobel Prize for Physiology or Medicine in 1985, and his significant industry experience gained through his service on the board of directors of the Company and of a leading pharmaceutical company, led the board to conclude that Dr. Brown should serve as a director.
As the Independent Director of Regeneron Pharmaceuticals, the total compensation of Michael Brown at Regeneron Pharmaceuticals is $719,993. There are 17 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis и Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: